Journal of Cardiovascular Pharmacology

Journal Logo

November 2022 - Volume 80 - Issue 5

  • George W. Booz, PhD, FAHA
  • 0160-2446
  • 1533-4023
  • 12 issues per year
  • Cardiac & Cardiovascular Systems 75/143, Pharmacology & Pharmacy 162/279
  • 3.271

Safety, Tolerability, and Effects of a Single Subcutaneous Administration of SP16 - a SERPIN-like, Small Peptide Agonist of the Low-Density Lipoprotein-like Receptor 1- on the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction (Benjamin W. Van Tassell, George F.  Wohlford, Marco Giuseppe Del Buono, Juan Ignacio Damonte, Roshanak Markley, Jeremy Turlington, Dinesh Kadariya, Azita Talasaz, Jane Ho, Amr Marawan, Georgia K. Thomas, Dana Austin, Cyrille Gineste, Cohava Gelber, Antonio Abbate). Modulation of the inflammatory response is a promising therapeutic strategy in acute myocardial infarction. The novel approach is based on the anti-inflammatory and cytoprotective properties mediated by the engagement of the low-density lipoprotein‒related protein 1 (LRP1) receptor. SERPIN peptide 16 (SP16) is a synthetic, selective LRP1 agonist. We herein present the results of a study with a single subcutaneous administration of SP16 in 10 patients with STEMI, to appraise its safety and tolerability and explore the effects on the acute inflammatory response, infarct size, and cardiac function…A single subcutaneous administration of SP16, a synthetic targeted LRP1 agonist, was safe and well-tolerated in patients with STEMI. A trend toward reduction in the inflammatory response and infarct size with SP16 was noted; however, the sample size for this study was not based on formal statistical criteria. More extensive studies are planned to determine the clinical efficacy of SP16 in STEMI. NCT: NCT04225533.



 ​

Current Issue Highlights




Original Article


Safety, Tolerability, and Effects of a Single Subcutaneous Administration of SP16 – a SERPIN-like, Small Peptide Agonist of the Low-Density Lipoprotein–like Receptor 1– on the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction

Van Tassell, Benjamin W.; Wohlford, George F.; Del Buono, Marco Giuseppe; More

Journal of Cardiovascular Pharmacology. 80(5):672-678, November 2022.


Ethoxyquin is a Competent Radical-Trapping Antioxidant for Preventing Ferroptosis in Doxorubicin Cardiotoxicity

Tadokoro, Tomonori; Ikeda, Masataka; Abe, Ko; More

Journal of Cardiovascular Pharmacology. 80(5):690-699, November 2022.



2021 Twitter logo - blue.pnglinkedinlogo.png

The editors of JCVP are calling for the submission of review articles dealing with all aspects of ER signaling in the heart, including the cGAS–cGAMP–STING pathway, mitochondria associated membranes, unfolded protein response (UPR), inflammasome activation, and ER stress. Articles with a therapeutic and disease-based perspective are welcomed. All articles will undergo peer review and appear in a regular issue in early 2023. Please contact the editorial office for additional information and prior approval for submission. ​​

The Journal of Cardiovascular Pharmacology announces an open call for a new review series dealing with the rapidly developing topic of RNA-based therapies. Reviews should focus on treating cardiovascular diseases or disorders, such as myocardial infarction, cardiac hypertrophy, cardiomyopathies, arrhythmias, valvular heart disease, aortic aneurysms, atherosclerosis and dysliidemia, and cerebrovascular disease. Various approaches, such as RNA aptamers, long non-coding RNAs, microRNAs, antisense nucleotides, and novel delivery strategies are included. The series is scheduled to appear early 2023. Please contact the editorial office for additional information and prior approval for submission.​​

`